pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 6·1 min read
save

Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

May 6, 2026·read at onclive ↗

Evolving Myeloma Care: Experts Align on Key Treatment StrategiesA 2025 expert consensus from Bridging the Gaps highlights the rapid evolution of multiple myeloma care and provides practical guidance to help clinicians navigate complex and expanding treatment options beyond existing guidelines.While quadruplet therapies are now favored in frontline treatment, uncertainty remains around their use in older patients, the role of stem cell transplant, and duration of maintenance therapy.Newer targeted treatments, including BCMA-directed therapies and CAR T-cell therapies, show strong benefits, with experts emphasizing early referral, careful sequencing considerations, and infection management to optimize patient outcomes.

source

Reporting by onclive.

read at onclive ↗
94 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Multiple Myeloma3BCMAInfectious Disease

related stories

  • Aug 17Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewFierce Biotech
  • Jul 16‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D winsFierce Biotech
  • 58m agoAbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma studyBioSpace
  • 21h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • 1d agoAbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialFierce Biotech